Invion (AU:IVX)
ASX:IVX
Want to see AU:IVX full AI Analyst Report?
Top Page
Invion
(Sydney:IVX)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.05
▼(-38.75% Downside)
Action:Reiterated
Date:05/19/26
The score is driven primarily by very weak financial performance (zero FY2025 revenue, widening losses, and persistent cash burn despite no debt). Technicals add further pressure with a clear downtrend and negative momentum, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Conservative leverage — no reported debt
The absence of reported debt materially reduces fixed financing costs and interest exposure, giving management flexibility to prioritize R&D and partnership deals. For a cash-burning biotech, no debt lowers near-term insolvency risk and preserves optionality for strategic funding or licensing choices over months.
Negative Factors
Zero revenue and widening net losses
A collapse to zero revenue alongside a materially larger net loss signals the company cannot currently monetize its assets or convert R&D into sales. Persisting negative margins erode capital and force continued external financing, reducing the firm's ability to self-fund development and increasing long-term dilution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage — no reported debt
The absence of reported debt materially reduces fixed financing costs and interest exposure, giving management flexibility to prioritize R&D and partnership deals. For a cash-burning biotech, no debt lowers near-term insolvency risk and preserves optionality for strategic funding or licensing choices over months.
Read all positive factors
Invion (IVX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.95M
Dividend YieldN/A
Average Volume (3M)97.01K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-100.00%
EPS Growth-31.21%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.13
Shares Outstanding96,965,320
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invion Business Overview & Revenue Model
Company Description
Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is ded...
How the Company Makes Money
Invion generates revenue through development funding and licensing agreements. The company's key partnerships, including those with strategic research collaborators, are significant contributors to its earnings, where these collaborators fund its ...
Invion Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 3.69M | 4.10M | 3.29M | 2.33M |
| Gross Profit | -1.59M | -1.29M | 1.00M | 1.21M | 969.12K | 810.50K |
| EBITDA | -5.16M | -4.00M | -4.57M | -965.37K | -1.82M | -1.29M |
| Net Income | -10.50M | -8.81M | -5.63M | -1.61M | -2.24M | -1.48M |
Balance Sheet | ||||||
| Total Assets | 8.09M | 9.49M | 15.45M | 19.05M | 20.04M | 5.64M |
| Cash, Cash Equivalents and Short-Term Investments | 137.54K | 850.37K | 783.53K | 4.08M | 8.47M | 1.04M |
| Total Debt | 627.68K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.38M | 1.24M | 1.01M | 650.63K | 462.41K | 851.50K |
| Stockholders Equity | 5.71M | 8.25M | 14.44M | 18.40M | 19.58M | 4.79M |
Cash Flow | ||||||
| Free Cash Flow | -2.61M | -2.97M | -3.30M | -4.39M | -8.36M | 417.98K |
| Operating Cash Flow | -2.61M | -2.97M | -2.40M | -1.81M | -1.11M | 417.98K |
| Investing Cash Flow | -22.68K | 0.00 | -900.00K | -2.58M | -7.25M | 0.00 |
| Financing Cash Flow | 2.04M | 3.04M | 0.00 | 15.80M | 15.80M | 0.00 |
Invion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$47.32M | -69.17 | -0.79% | ― | 6.80% | 98.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$16.45M | -4.15 | -29.05% | ― | 6.14% | -20.00% | |
43 Neutral | AU$6.85M | -0.79 | -110.74% | ― | ― | 49.10% | |
43 Neutral | AU$19.73M | -2.87 | 4388.00% | ― | -53.90% | 57.52% | |
42 Neutral | AU$4.95M | -0.56 | -150.48% | ― | -100.00% | -31.21% | |
41 Neutral | AU$4.22M | -0.39 | 258.94% | ― | 17.56% | 75.11% |
* Healthcare Sector Average
AU:IVX
Invion
0.05
-0.03
-35.37%
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:RGT
Argent Biopharma
0.04
-0.08
-66.96%
AU:MVP
Medical Developments International Limited
0.41
-0.14
-25.45%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-32.00%
AU:IDT
IDT Australia Limited
0.04
-0.06
-59.18%
Invion Corporate Events
Invion corrects director shareholding disclosure in ASX filing
May 11, 2026
Invion Limited has disclosed that an indirect shareholding of director Alistair Bennallack, held via a superannuation fund, was omitted from earlier director interest notices lodged in 2020 and 2025, and has now filed a corrected Appendix 3Y with ...
Invion Options Lapse, Trimming Potential Future Dilution
May 1, 2026
Invion Limited has reported a change in its capital structure relating to listed options on the Australian Securities Exchange. The company advised that a series of options with a $1.00 exercise price, due to expire on 1 May 2026, have lapsed unex...
Invion bolsters funding as Photosoft cancer programs show promising progress
Apr 30, 2026
Invion reported a modest cash balance at the end of the March quarter, supported by a two-tranche $1.3 million convertible note offering backed by its executive chair and a major shareholder, to fund ongoing cancer trials, partner-supported studie...
Invion convenes virtual general meeting to vote on fair and reasonable transaction
Apr 28, 2026
Invion Limited has called a virtual General Meeting of shareholders to be held on 29 May 2026 at 4:00pm AEST, using online conferencing technology that allows real-time questions and poll-based voting. Shareholders are encouraged to register in ad...
Invion to Showcase Photodynamic Cancer Therapy at Major Asian Biotech Conferences
Apr 21, 2026
Invion Limited, the ASX-listed life-science company developing Photosoft-based next generation photodynamic therapy for cancer and infectious diseases, is expanding its international profile through a series of conference appearances. The company&...
Invion Expands INV043 Skin Cancer Trial to Basal Cell Carcinoma After Strong Safety Data
Apr 21, 2026
Invion has advanced its clinical program for INV043 in non-melanoma skin cancer by progressing to the final phase of its current trial and expanding enrolment to patients with basal cell carcinoma. This move follows approval from the Safety Review...
Invion Updates Director Interest Disclosure to Strengthen Governance
Apr 20, 2026
Invion has clarified that earlier director interest notices for executive chair and CEO Thian Chew did not include certain interests held by substantial shareholder Honsue Cho and his associates, as these were not strictly required under ASX Listi...
Invion Updates Market on Director Chiat Thian Chew’s Expanded Associated Holdings
Apr 20, 2026
Invion Limited has disclosed changes to the relevant interests of director Chiat Thian Chew in the company’s securities, as required under ASX listing rules. The notice details both his direct holdings in ordinary shares and unlisted options...
Invion Plans New Issue of 3.2 Million Options on ASX
Mar 23, 2026
Invion Limited has notified the Australian Securities Exchange of a proposed issue of new securities as part of a placement or similar capital-raising transaction. The company plans to issue up to 3,177,324 options in a new class, expiring on 12 M...
Invion Plans Share and Option Issue to Strengthen Capital Base
Mar 23, 2026
Invion Limited has notified the ASX of a proposed capital raising through the issue of up to 5,000,000 new ordinary fully paid shares and 5,000,000 options expiring on 30 June 2027. The securities are to be issued via a placement or similar mechan...
Invion Plans New Option Issue to Support Capital Management
Mar 23, 2026
Invion Limited has notified the ASX of a proposed issue of new options as part of a placement or similar capital raising initiative. The company plans to issue up to 3,532,494 options, expiring on 12 May 2029 with no exercise price, under a new cl...
Invion plans issue of new class of ASX-listed options
Mar 23, 2026
Invion Limited has notified the ASX of its intention to issue a new class of options as part of a placement or similar capital-raising transaction. The proposed securities are options expiring on 12 May 2029, with no exercise price, and a maximum ...
Invion plans new listed option issue to support capital structure
Mar 18, 2026
Invion Limited has notified the ASX of a proposed issue of new options as part of a placement or similar capital-raising structure, signalling an active approach to managing its funding and capital mix. The company has applied for quotation of the...
Invion Issues New Unquoted Options Under Employee Incentive Scheme
Mar 12, 2026
Invion Limited has notified the market of the issue of 200,000 unquoted options under its employee incentive scheme, exercisable at $0.12 and expiring on 27 February 2029. The new options, which are not intended to be quoted on the ASX, reflect th...
Invion Issues New Shares as It Explores Expansion of Cancer Therapy Program
Mar 5, 2026
Invion Limited has issued 11,318,060 fully paid ordinary shares following the maturity of 72,024 unlisted convertible notes, confirming that the issuance was conducted without a prospectus under relevant Corporations Act provisions and that it rem...
Invion Seeks ASX Quotation for 11.3 Million New Shares
Mar 5, 2026
Invion Limited has applied to the Australian Securities Exchange for quotation of 11,318,060 new ordinary fully paid shares, with an issue date of March 5, 2026. The additional shares arise from the exercise of options or conversion of other secur...
Invion Raises Capital via Convertible Notes to Accelerate Cancer Programs
Mar 4, 2026
Invion has issued 578,118 unsecured convertible notes under Tranche 1 of a capital raising, securing approximately $578,118 in gross proceeds from sophisticated and professional investors. The issue was conducted under the company’s existing...
Invion Issues Unquoted Convertible Notes to Bolster Funding Strategy
Mar 4, 2026
Invion Limited has notified the market of the issue of 578,118 unquoted convertible notes maturing on 4 March 2029, with an issue date of 5 March 2026. These securities form part of a previously announced transaction and are not intended to be quo...
Invion Loss Widens as Auditors Flag Going-Concern Risk
Feb 27, 2026
Invion Limited has reported a sharp deterioration in its financial position for the half-year ended 31 December 2025, with loss after tax attributable to owners jumping 90.5% to $3.57 million compared with the prior corresponding period. The compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.